Process for producing GM2 specific antibodies

Details Process for producing GM2 specific antibodies Process for producing GM2 specific antibodies

1995-06-16

2000-05-02

Scheiner, Toni R.

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

435 732, 436543, 436547, G01N 33574, G01N 3353

Patent

active

060571152

ABSTRACT:
The invention relates to the production of ganglioside specific antibodies. These antibodies are produced following immunization with lipopolysaccharide antigen of Campylobacter jejuni. The antibodies bind to monosialogangliosides, including GM2 and GM1.

REFERENCES:
patent: 4557931 (1985-12-01), Irie et al.
patent: 5169757 (1992-12-01), Yamazaki et al.
patent: 5200344 (1993-04-01), Blaser et al.
patent: 5229289 (1993-07-01), Kjeldsen et al.
patent: 5240833 (1993-08-01), Nudelman et al.
patent: 5260057 (1993-11-01), Cordle et al.
patent: 5308614 (1994-05-01), Hakomori
Ritter, et al., Int. J. Cancer, vol. 64, pp. 184-190, 1996.
Wirguin, et al., Neurology, vol. 45 (Suppl. 4), abstract 909S, p. A416, Apr. 1995.
Suturkova-Milosevic, et al., vol. 64, Suppl., Abstract B, p. S89, 1995.
Jacobs et al., "Serum Anti-GQ1b IgG Antibodies Recognize Surface Epitopes on Campylobacter jejuni From Patients With Miller Fisher Syndrome," Ann. Neurol 37(2): 260-264 (Feb. 1995).
Yuki, et al., Molecular Mimicry Between GQ1b Ganglioside and Lipopolysaccharides of Campylobacter jejuni Isolated from Patients With Fisher's Syndrome Ann. Neurol 36(5): 791-793 (Nov. 1994).
Aspinall, et al., Lipopolysaccharides From Campylobacter jejuni Associated With Guillain Barre Syndrome Patients Mimic Human Gangliosides In Structure. Infection and Immunity 62(5): 2122-2125 May 1994.
Wirgun, et al., Monoclonal IgM Antibodies toi GM1 ans Asialo GM1 In Chronic Neuropathies Cross-React with Campylobacter jejuni Lipopolysaccharides Ann Neurol 35(6): 698-703 (Jun. 1994).
Livingston, et al, "Improved Survival In Stage III Melanoma Patients With GM2 Antibodies: A Randomized Trial of Adjuvant Vaccination With GM2 Ganglioside" J. Clin Oncol 12(5): 1036-1044 1944.
Aspinall, et al., Lipopolysaccharides of Campylobacter jejuni Serotype 0:19: Structures of Core Oligosaccharide Regions From The Serostrain And Two Bacterial Isolates From Patients With The Guillain --Barre Syndrome Biochem 33:241-249 (1994).
Yuki, et al., Penner's Serotype 4 of Campylobacter jejuni Has A Lypopolysaccharide That Bears A GD1a Epitope Infec & Immun: 62(5): 2101-2103 (May 1994).
Aspinall, et al. "Chemical Structures of the Core Regions of Campylobacter jejuni Serotypes 0:1, 0:4, 0:3, and 0:36 Lypopolysaccharides." Rur. J. Biochem 213: 1017-1027 (1993).
Aspinall, et al, Serological Diversity and Chemical Structures of Campylobacter jejuni Low--Molecular Weight Lypopolysaccharides J. Bacteriol 171(4): 1324-1332 (1992).
Walsh, et al., "Association Between Glycoconjugate Antibodies And Campylobacter Infection In Patients With Guillain Barre Syndrome" J. Neuroimmunol 34:43-51 (1991).
Goldman, et al., Electrophoretic Separation of Lipopolysaccharide Monomers Differing In Polysaccharide Length Meth. Enzymal 138: 267-275 (1987).
Livingston, et al., "Vacines containing Purified GM2 Ganglioside Elicit GM2 Antibodies In Melanoma Patients" Proc. Nat'l Acad. Sci USA 84: 2911-2915 (May 1987).
Yuki, et al., "A Bacteriums' Lypopolysaccharide That Elicits Guillain -Barre Syndrome Has A GM1 Gangleoside -Like Structure" J. Exp. Med. 178: 1771-1775 (Nov. 1993).

Affiliated with

Also associated with

Rating

Process for producing GM2 specific antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Process for producing GM2 specific antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for producing GM2 specific antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1592761